These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15101503)

  • 1. The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective.
    Chue P
    Can J Psychiatry; 2004 Mar; 49(3):200-7. PubMed ID: 15101503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care.
    Nasrallah HA; Newcomer JW
    J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S7-14. PubMed ID: 15356415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.
    Barnett AH; Mackin P; Chaudhry I; Farooqi A; Gadsby R; Heald A; Hill J; Millar H; Peveler R; Rees A; Singh V; Taylor D; Vora J; Jones PB
    J Psychopharmacol; 2007 Jun; 21(4):357-73. PubMed ID: 17656425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of metabolic impairments inducted by atypical antipsychotics among schizophrenic patients].
    Gauthé M; Goldberger C; Olié JP; Lôo H; Gury C; Poirier MF
    Encephale; 2005; 31(1 Pt 1):18-23. PubMed ID: 15971636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.
    Newcomer JW; Nasrallah HA; Loebel AD
    J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S1-6. PubMed ID: 15356414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus development conference on antipsychotic drugs and obesity and diabetes.
    ; ; ;
    Obes Res; 2004 Feb; 12(2):362-8. PubMed ID: 14981231
    [No Abstract]   [Full Text] [Related]  

  • 9. Dyslipidemia and atypical antipsychotic drugs.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 18():27-35. PubMed ID: 15600382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of monitoring practices in patients on second generation antipsychotics.
    Nguyen D; Brakoulias V; Boyce P
    Australas Psychiatry; 2009 Aug; 17(4):295-9. PubMed ID: 19585292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic risk during antipsychotic treatment.
    Newcomer JW
    Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schizophrenia and obesity: impact of antipsychotic medications.
    Wirshing DA
    J Clin Psychiatry; 2004; 65 Suppl 18():13-26. PubMed ID: 15600381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atypical antipsychotic induced weight gain and metabolic disorders].
    Rojas G P; Poblete A C; Orellana G X; Rouliez A K; Liberman G C
    Rev Med Chil; 2009 Jan; 137(1):106-14. PubMed ID: 19399331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
    Henderson DC; Cagliero E; Gray C; Nasrallah RA; Hayden DL; Schoenfeld DA; Goff DC
    Am J Psychiatry; 2000 Jun; 157(6):975-81. PubMed ID: 10831479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic implications of adverse effects during antipsychotic drug therapy.
    Nasrallah HA
    Am J Health Syst Pharm; 2002 Nov; 59(22 Suppl 8):S16-21. PubMed ID: 12455295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
    Casey DE; Haupt DW; Newcomer JW; Henderson DC; Sernyak MJ; Davidson M; Lindenmayer JP; Manoukian SV; Banerji MA; Lebovitz HE; Hennekens CH
    J Clin Psychiatry; 2004; 65 Suppl 7():4-18; quiz 19-20. PubMed ID: 15151456
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic effects of treatment with atypical antipsychotics.
    Kane JM; Barrett EJ; Casey DE; Correll CU; Gelenberg AJ; Klein S; Newcomer JW
    J Clin Psychiatry; 2004 Nov; 65(11):1447-55. PubMed ID: 15554755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.